vs
Side-by-side financial comparison of Adaptive Biotechnologies Corp (ADPT) and BYLINE BANCORP, INC. (BY). Click either name above to swap in a different company.
BYLINE BANCORP, INC. is the larger business by last-quarter revenue ($112.4M vs $71.7M, roughly 1.6× Adaptive Biotechnologies Corp). BYLINE BANCORP, INC. runs the higher net margin — 33.4% vs -18.9%, a 52.4% gap on every dollar of revenue. On growth, Adaptive Biotechnologies Corp posted the faster year-over-year revenue change (51.0% vs 9.0%). Over the past eight quarters, Adaptive Biotechnologies Corp's revenue compounded faster (30.8% CAGR vs 6.4%).
ExpreS2ion Biotechnologies is a Danish biotechnology company specialised in the development of new vaccines and immunotherapy products based in Hørsholm, Denmark and listed on the Nasdaq First North Growth Market Sweden.
Byline Bank is a bank headquartered in Chicago, Illinois, United States. It is the primary subsidiary of Byline Bancorp, Inc., a bank holding company, and the 4th largest SBA 7(a) lender.
ADPT vs BY — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $71.7M | $112.4M |
| Net Profit | $-13.6M | $37.6M |
| Gross Margin | 74.6% | — |
| Operating Margin | -17.8% | — |
| Net Margin | -18.9% | 33.4% |
| Revenue YoY | 51.0% | 9.0% |
| Net Profit YoY | 59.7% | 33.0% |
| EPS (diluted) | $-0.08 | $0.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $112.4M | ||
| Q4 25 | $71.7M | $117.0M | ||
| Q3 25 | $94.0M | $115.7M | ||
| Q2 25 | $58.9M | $110.5M | ||
| Q1 25 | $52.4M | $103.1M | ||
| Q4 24 | $47.5M | $104.7M | ||
| Q3 24 | $46.4M | $101.8M | ||
| Q2 24 | $43.2M | $99.4M |
| Q1 26 | — | $37.6M | ||
| Q4 25 | $-13.6M | $34.5M | ||
| Q3 25 | $9.5M | $37.2M | ||
| Q2 25 | $-25.6M | $30.1M | ||
| Q1 25 | $-29.9M | $28.2M | ||
| Q4 24 | $-33.7M | $30.3M | ||
| Q3 24 | $-32.1M | $30.3M | ||
| Q2 24 | $-46.2M | $29.7M |
| Q1 26 | — | — | ||
| Q4 25 | 74.6% | — | ||
| Q3 25 | 80.7% | — | ||
| Q2 25 | 69.4% | — | ||
| Q1 25 | 67.6% | — | ||
| Q4 24 | 62.0% | — | ||
| Q3 24 | 64.1% | — | ||
| Q2 24 | 55.3% | — |
| Q1 26 | — | — | ||
| Q4 25 | -17.8% | 40.1% | ||
| Q3 25 | 10.9% | 43.1% | ||
| Q2 25 | -42.5% | 35.2% | ||
| Q1 25 | -56.4% | 36.4% | ||
| Q4 24 | -71.3% | 38.6% | ||
| Q3 24 | -70.3% | 39.3% | ||
| Q2 24 | -109.6% | 40.4% |
| Q1 26 | — | 33.4% | ||
| Q4 25 | -18.9% | 34.1% | ||
| Q3 25 | 10.2% | 32.1% | ||
| Q2 25 | -43.5% | 27.2% | ||
| Q1 25 | -56.9% | 27.4% | ||
| Q4 24 | -71.0% | 34.3% | ||
| Q3 24 | -69.1% | 29.8% | ||
| Q2 24 | -107.0% | 29.9% |
| Q1 26 | — | $0.83 | ||
| Q4 25 | $-0.08 | $0.77 | ||
| Q3 25 | $0.06 | $0.82 | ||
| Q2 25 | $-0.17 | $0.66 | ||
| Q1 25 | $-0.20 | $0.64 | ||
| Q4 24 | $-0.22 | $0.68 | ||
| Q3 24 | $-0.22 | $0.69 | ||
| Q2 24 | $-0.31 | $0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $70.5M | $198.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $218.8M | $1.3B |
| Total Assets | $512.7M | $9.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $198.4M | ||
| Q4 25 | $70.5M | $149.1M | ||
| Q3 25 | $55.0M | $259.0M | ||
| Q2 25 | $43.2M | $218.3M | ||
| Q1 25 | $50.6M | $421.3M | ||
| Q4 24 | $47.9M | $563.1M | ||
| Q3 24 | $38.1M | $452.6M | ||
| Q2 24 | $59.8M | $730.5M |
| Q1 26 | — | $1.3B | ||
| Q4 25 | $218.8M | $1.3B | ||
| Q3 25 | $204.4M | $1.2B | ||
| Q2 25 | $179.7M | $1.2B | ||
| Q1 25 | $190.4M | $1.1B | ||
| Q4 24 | $202.7M | $1.1B | ||
| Q3 24 | $223.8M | $1.1B | ||
| Q2 24 | $241.6M | $1.0B |
| Q1 26 | — | $9.9B | ||
| Q4 25 | $512.7M | $9.7B | ||
| Q3 25 | $490.6M | $9.8B | ||
| Q2 25 | $496.6M | $9.7B | ||
| Q1 25 | $510.9M | $9.6B | ||
| Q4 24 | $539.4M | $9.5B | ||
| Q3 24 | $558.5M | $9.4B | ||
| Q2 24 | $584.9M | $9.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.1M | — |
| Free Cash FlowOCF − Capex | $1.4M | — |
| FCF MarginFCF / Revenue | 2.0% | — |
| Capex IntensityCapex / Revenue | 0.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-48.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $2.1M | $140.3M | ||
| Q3 25 | $-7.1M | $38.3M | ||
| Q2 25 | $-12.4M | $16.3M | ||
| Q1 25 | $-28.5M | $27.1M | ||
| Q4 24 | $-12.5M | $175.2M | ||
| Q3 24 | $-27.1M | $19.8M | ||
| Q2 24 | $-17.3M | $40.1M |
| Q1 26 | — | — | ||
| Q4 25 | $1.4M | $136.3M | ||
| Q3 25 | $-7.5M | $38.0M | ||
| Q2 25 | $-13.1M | $15.2M | ||
| Q1 25 | $-29.7M | $25.0M | ||
| Q4 24 | $-12.6M | $171.2M | ||
| Q3 24 | $-27.4M | $19.1M | ||
| Q2 24 | $-19.0M | $39.4M |
| Q1 26 | — | — | ||
| Q4 25 | 2.0% | 116.5% | ||
| Q3 25 | -8.0% | 32.8% | ||
| Q2 25 | -22.2% | 13.7% | ||
| Q1 25 | -56.7% | 24.3% | ||
| Q4 24 | -26.5% | 163.5% | ||
| Q3 24 | -59.0% | 18.8% | ||
| Q2 24 | -44.1% | 39.7% |
| Q1 26 | — | — | ||
| Q4 25 | 0.9% | 3.4% | ||
| Q3 25 | 0.4% | 0.3% | ||
| Q2 25 | 1.1% | 1.0% | ||
| Q1 25 | 2.4% | 2.0% | ||
| Q4 24 | 0.2% | 3.8% | ||
| Q3 24 | 0.7% | 0.6% | ||
| Q2 24 | 4.0% | 0.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 4.06× | ||
| Q3 25 | -0.75× | 1.03× | ||
| Q2 25 | — | 0.54× | ||
| Q1 25 | — | 0.96× | ||
| Q4 24 | — | 5.78× | ||
| Q3 24 | — | 0.65× | ||
| Q2 24 | — | 1.35× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
BY
Segment breakdown not available.
